BFIM
BMRN icon

Beese Fulmer Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Beese Fulmer Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Sell
6,246
-1,360
-18% -$74.5K 0.02% 260
2026
Q1 		$430K Buy
7,606
+1,310
+21% +$76.4K 0.03% 232
2025
Q4 		$374K Buy
+6,296
New +$343K 0.02% 245

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Beese Fulmer Investment Management's BMRN Position: Q2 2026 in Review

Beese Fulmer Investment Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 18% in Q2 2026, selling an estimated $74.5K and leaving 6,246 shares worth $357K. The position accounts for 0.02% of the portfolio, ranked #260.

Beese Fulmer Investment Management first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $430K in Q1 2026. 150 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Beese Fulmer Investment Management held 6,246 shares of BioMarin Pharmaceuticals worth $357K as of Q2 2026.
  • Beese Fulmer Investment Management sold 1,360 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $74.5K.
  • BioMarin Pharmaceuticals made up 0.02% of Beese Fulmer Investment Management's portfolio in Q2 2026, its #260 holding.
  • Beese Fulmer Investment Management first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Beese Fulmer Investment Management's BioMarin Pharmaceuticals position peaked at $430K in Q1 2026.
  • 150 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Beese Fulmer Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.